Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis

The Histiocytosis study group of the Japanese Society of Pediatric Hematology/Oncology

Research output: Contribution to journalArticle

Abstract

The efficacy of and indications for hematopoietic stem cell transplantation (HSCT) in pediatric Langerhans cell histiocytosis (LCH) remain undetermined. This retrospective study analyzed 30 children with refractory LCH who underwent HSCT in Japan between 1996 and 2014. Eleven patients received a myeloablative conditioning (MAC) regimen, while 19 patients received a reduced-intensity conditioning (RIC) regimen. Among the 26 patients with complete data, 23 patients had risk organ (RO) involvement during clinical course. Disease status at HSCT was no active disease (NAD) (4), active disease-regression (AD-r) (2), active disease-stable (AD-s) (4), and active disease-progressive (AD-p) (16). Seventeen of the 30 patients (57%) were alive with a median follow-up of 433 days (range 9–5307) after HSCT. Death occurred within 3 months after HSCT in eight of 13 patients. RIC and MAC patients were similar in both overall survival (OS) (56.8% vs. 63.6%, respectively, p = 0.789) and failure-free survival (56.8% vs. 54.6%, respectively, p = 0.938). Regarding disease status at HSCT, the six patients with NAD/AD-r experienced better outcomes than the 20 with AD-s/AD-p (5-year OS, 100% vs. 54.5%, respectively, p = 0.040). Disease state at the time of HSCT was the most important prognostic factor.

Original languageEnglish
JournalInternational journal of hematology
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Langerhans Cell Histiocytosis
Hematopoietic Stem Cell Transplantation
Survival
Japan
Retrospective Studies
Pediatrics

Keywords

  • Hematopoietic stem cell transplantation (HSCT)
  • Reduced-intensity conditioning (RIC)
  • Refractory Langerhans cell histiocytosis (LCH)

ASJC Scopus subject areas

  • Hematology

Cite this

Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis. / The Histiocytosis study group of the Japanese Society of Pediatric Hematology/Oncology.

In: International journal of hematology, 01.01.2019.

Research output: Contribution to journalArticle

@article{59039fb4153e425cad4e4db151bb0387,
title = "Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis",
abstract = "The efficacy of and indications for hematopoietic stem cell transplantation (HSCT) in pediatric Langerhans cell histiocytosis (LCH) remain undetermined. This retrospective study analyzed 30 children with refractory LCH who underwent HSCT in Japan between 1996 and 2014. Eleven patients received a myeloablative conditioning (MAC) regimen, while 19 patients received a reduced-intensity conditioning (RIC) regimen. Among the 26 patients with complete data, 23 patients had risk organ (RO) involvement during clinical course. Disease status at HSCT was no active disease (NAD) (4), active disease-regression (AD-r) (2), active disease-stable (AD-s) (4), and active disease-progressive (AD-p) (16). Seventeen of the 30 patients (57{\%}) were alive with a median follow-up of 433 days (range 9–5307) after HSCT. Death occurred within 3 months after HSCT in eight of 13 patients. RIC and MAC patients were similar in both overall survival (OS) (56.8{\%} vs. 63.6{\%}, respectively, p = 0.789) and failure-free survival (56.8{\%} vs. 54.6{\%}, respectively, p = 0.938). Regarding disease status at HSCT, the six patients with NAD/AD-r experienced better outcomes than the 20 with AD-s/AD-p (5-year OS, 100{\%} vs. 54.5{\%}, respectively, p = 0.040). Disease state at the time of HSCT was the most important prognostic factor.",
keywords = "Hematopoietic stem cell transplantation (HSCT), Reduced-intensity conditioning (RIC), Refractory Langerhans cell histiocytosis (LCH)",
author = "{The Histiocytosis study group of the Japanese Society of Pediatric Hematology/Oncology} and Kazuko Kudo and Miho Maeda and Nobuhiro Suzuki and Hirokazu Kanegane and Shouichi Ohga and Eiichi Ishii and Yoko Shioda and Toshihiko Imamura and Shinsaku Imashuku and Yukiko Tsunematsu and Mikiya Endo and Akira Shimada and Yuuki Koga and Yoshiko Hashii and Maiko Noguchi and Masami Inoue and Ken Tabuchi and Akira Morimoto",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12185-019-02760-5",
language = "English",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis

AU - The Histiocytosis study group of the Japanese Society of Pediatric Hematology/Oncology

AU - Kudo, Kazuko

AU - Maeda, Miho

AU - Suzuki, Nobuhiro

AU - Kanegane, Hirokazu

AU - Ohga, Shouichi

AU - Ishii, Eiichi

AU - Shioda, Yoko

AU - Imamura, Toshihiko

AU - Imashuku, Shinsaku

AU - Tsunematsu, Yukiko

AU - Endo, Mikiya

AU - Shimada, Akira

AU - Koga, Yuuki

AU - Hashii, Yoshiko

AU - Noguchi, Maiko

AU - Inoue, Masami

AU - Tabuchi, Ken

AU - Morimoto, Akira

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The efficacy of and indications for hematopoietic stem cell transplantation (HSCT) in pediatric Langerhans cell histiocytosis (LCH) remain undetermined. This retrospective study analyzed 30 children with refractory LCH who underwent HSCT in Japan between 1996 and 2014. Eleven patients received a myeloablative conditioning (MAC) regimen, while 19 patients received a reduced-intensity conditioning (RIC) regimen. Among the 26 patients with complete data, 23 patients had risk organ (RO) involvement during clinical course. Disease status at HSCT was no active disease (NAD) (4), active disease-regression (AD-r) (2), active disease-stable (AD-s) (4), and active disease-progressive (AD-p) (16). Seventeen of the 30 patients (57%) were alive with a median follow-up of 433 days (range 9–5307) after HSCT. Death occurred within 3 months after HSCT in eight of 13 patients. RIC and MAC patients were similar in both overall survival (OS) (56.8% vs. 63.6%, respectively, p = 0.789) and failure-free survival (56.8% vs. 54.6%, respectively, p = 0.938). Regarding disease status at HSCT, the six patients with NAD/AD-r experienced better outcomes than the 20 with AD-s/AD-p (5-year OS, 100% vs. 54.5%, respectively, p = 0.040). Disease state at the time of HSCT was the most important prognostic factor.

AB - The efficacy of and indications for hematopoietic stem cell transplantation (HSCT) in pediatric Langerhans cell histiocytosis (LCH) remain undetermined. This retrospective study analyzed 30 children with refractory LCH who underwent HSCT in Japan between 1996 and 2014. Eleven patients received a myeloablative conditioning (MAC) regimen, while 19 patients received a reduced-intensity conditioning (RIC) regimen. Among the 26 patients with complete data, 23 patients had risk organ (RO) involvement during clinical course. Disease status at HSCT was no active disease (NAD) (4), active disease-regression (AD-r) (2), active disease-stable (AD-s) (4), and active disease-progressive (AD-p) (16). Seventeen of the 30 patients (57%) were alive with a median follow-up of 433 days (range 9–5307) after HSCT. Death occurred within 3 months after HSCT in eight of 13 patients. RIC and MAC patients were similar in both overall survival (OS) (56.8% vs. 63.6%, respectively, p = 0.789) and failure-free survival (56.8% vs. 54.6%, respectively, p = 0.938). Regarding disease status at HSCT, the six patients with NAD/AD-r experienced better outcomes than the 20 with AD-s/AD-p (5-year OS, 100% vs. 54.5%, respectively, p = 0.040). Disease state at the time of HSCT was the most important prognostic factor.

KW - Hematopoietic stem cell transplantation (HSCT)

KW - Reduced-intensity conditioning (RIC)

KW - Refractory Langerhans cell histiocytosis (LCH)

UR - http://www.scopus.com/inward/record.url?scp=85075483920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075483920&partnerID=8YFLogxK

U2 - 10.1007/s12185-019-02760-5

DO - 10.1007/s12185-019-02760-5

M3 - Article

C2 - 31758416

AN - SCOPUS:85075483920

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

ER -